The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.10, 2012-10, pp. : 1585-1588

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia

Current Pharmaceutical Design, Vol. 23, Iss. 10, 2017-05 ,pp. : 1484-1494

Bentham Science Publishers

Access to resources Recommend Favorite

PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?

Current Pharmaceutical Design, Vol. 19, Iss. 21, 2013-01 ,pp. : 3869-3877

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia

By Wierzbicki Anthony S Hardman Timothy C Viljoen Adie

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 5, 2012-05 ,pp. : 667-676

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic potential of serum and glucocorticoid inducible kinase inhibition

By Lang Florian Voelkl Jakob

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 701-714

Informa Healthcare

Access to resources Recommend Favorite

The Therapeutic Potential of VEGF Inhibition in Diabetic Microvascular Complications

By Tremolada Gemma

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 6, 2007-01 ,pp. : 393-398

Adis International

Access to resources Recommend Favorite